Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -27.0%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $53601 | $25M | $8M | $9M | $30M | $44M | $42M | — | — | — |
| Enterprise Value | $-8018391 | $17M | $649555 | $2M | $20M | $31M | $27M | — | — | — |
| P/E Ratio → | -0.01 | — | — | — | — | 185.42 | 9.50 | — | — | — |
| P/S Ratio | 0.00 | 2.16 | 0.53 | 0.47 | 2.11 | 2.72 | 2.36 | — | — | — |
| P/B Ratio | 0.00 | 1.09 | 0.35 | 0.43 | 0.90 | 1.36 | 1.33 | — | — | — |
| P/FCF | 0.08 | 35.52 | — | — | — | 41.80 | — | — | — | — |
| P/OCF | 0.06 | 29.11 | — | 168.55 | — | 15.51 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.45 | 0.04 | 0.12 | 1.42 | 1.88 | 1.52 | — | — | — |
| EV / EBITDA | — | — | 7.46 | — | — | 80.26 | 5.59 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | 6.10 | — | — | — |
| EV / FCF | — | 23.87 | — | — | — | 28.89 | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 42.5% | 42.5% | 56.2% | 43.8% | 44.9% | 57.9% | 66.0% | 68.7% | 65.4% | 59.6% |
| Operating Margin | -54.4% | -54.4% | -2.2% | -68.4% | -20.9% | -2.0% | 25.0% | 24.5% | 25.5% | 10.7% |
| Net Profit Margin | -55.5% | -55.5% | -4.1% | -58.3% | -20.8% | 1.5% | 24.8% | 27.2% | 23.5% | 15.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.0% | -27.0% | -2.8% | -41.9% | -9.0% | 0.7% | 18.9% | 30.3% | 36.4% | 29.4% |
| ROA | -25.1% | -25.1% | -2.6% | -36.0% | -7.9% | 0.7% | 17.0% | 25.5% | 28.7% | 21.9% |
| ROIC | -30.1% | -30.1% | -1.7% | -53.1% | -10.5% | -1.3% | 27.3% | 45.6% | 76.6% | 35.4% |
| ROCE | -26.3% | -26.3% | -1.5% | -47.3% | -8.8% | -1.0% | 19.0% | 26.9% | 38.2% | 19.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.05 | 0.01 | 0.00 | 0.02 | 0.06 | — |
| Debt / EBITDA | — | — | 0.66 | — | — | 0.53 | 0.01 | 0.08 | 0.22 | — |
| Net Debt / Equity | — | -0.36 | -0.32 | -0.32 | -0.30 | -0.42 | -0.47 | -0.49 | -0.63 | -0.57 |
| Net Debt / EBITDA | — | — | -89.38 | — | — | -35.88 | -3.07 | -1.94 | -2.18 | -2.80 |
| Debt / FCF | — | -11.65 | — | — | — | -12.91 | — | -79.30 | -11.16 | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($8M) exceeds total debt ($26083)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.11 | 11.11 | 12.22 | 6.99 | 5.45 | 7.59 | 9.83 | 5.88 | 5.36 | 4.10 |
| Quick Ratio | 11.11 | 11.11 | 11.84 | 6.76 | 5.41 | 7.59 | 9.83 | 5.88 | 5.36 | 4.10 |
| Cash Ratio | 9.12 | 9.12 | 8.55 | 5.02 | 2.89 | 3.96 | 5.74 | 3.32 | 3.89 | 3.07 |
| Asset Turnover | — | 0.47 | 0.61 | 0.80 | 0.37 | 0.45 | 0.52 | 0.84 | 0.92 | 1.41 |
| Inventory Turnover | — | — | 11.86 | 18.44 | 41.22 | — | — | — | — | — |
| Days Sales Outstanding | — | 92.48 | 109.98 | 56.64 | 235.58 | 276.62 | 210.08 | 126.68 | 56.55 | 48.41 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 0.5% | 10.5% | — | — | — |
| FCF Yield | 100.0% | 2.8% | — | — | — | 2.4% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $36756 | $6997 | $3499 | $3494 | $3352 | $3351 | $3444 | $3367 | $3367 |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ZCMD stock.
Zhongchao Inc.'s current P/E ratio is -0.0x. The historical average is 97.5x.
Zhongchao Inc.'s return on equity (ROE) is -27.0%. The historical average is 3.9%.
Based on historical data, Zhongchao Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
Zhongchao Inc. has 42.5% gross margin and -54.4% operating margin.
Key Metrics
Top Statement Risk
Capital erosion and burn
Market Pricing Reflects Distressed Status
As reported in recent financial filings, ZCMD's P/S ratio of 0.00 and negative P/E multiple suggest that the market is currently pricing the company as a distressed asset rather than a growth-oriented healthcare information services provider, effectively ignoring its remaining cash reserves in the valuation.
The absence of a meaningful P/E or EV/EBITDA multiple indicates that investors have largely abandoned growth expectations for the firm. Given the persistent revenue decline, the current valuation appears to be anchored solely to the company's net cash position, implying that the core operating business is viewed as having little to no terminal value.
Capital Compounding Remains Deeply Negative
Based on the latest quarterly data, ZCMD's ROIC has plummeted to -27.1% in 2025Q4, illustrating a severe decay in capital efficiency that suggests the company is currently destroying shareholder value rather than generating returns on its invested capital base.
The consistent negative trend in ROIC over the last ten quarters highlights a fundamental inability to deploy capital effectively within the medical education niche. This decay is driven by both contracting margins and an inability to scale revenue, suggesting that the current business model is structurally incapable of achieving positive returns on invested capital.
Working Capital Efficiency Shows Instability
According to recent financial statements, ZCMD's DSO has fluctuated significantly, reaching 51 days in 2025Q4, which indicates inconsistent collection cycles and potential challenges in managing customer leverage within the highly competitive Chinese healthcare information services market.
The volatility in DSO, which previously spiked as high as 169 days, suggests that the company lacks strong bargaining power over its pharmaceutical clients. This inefficiency in working capital management exacerbates the company's cash burn, as the timing of revenue recognition often fails to align with the immediate cash requirements of the business.
Liquidity Buffer Masks Operational Fragility
As reported in quarterly filings, ZCMD maintains a current ratio of 11.11, which appears superficially strong but is primarily a function of the company's shrinking asset base and lack of debt rather than robust operational liquidity or high-quality current assets.
While the absence of debt provides a temporary safety net, the high current ratio is misleading because it does not account for the rapid depletion of cash reserves to fund ongoing operating losses. Investors should monitor the burn rate closely, as the current liquidity position may provide a false sense of security in the face of persistent negative cash flow.
Misapplication of Tech Platform Multiples
Based on an analysis of the business model, the market's tendency to apply SaaS-like valuation multiples to ZCMD is fundamentally flawed, as the company operates as a project-based service agency rather than a scalable, high-margin digital platform.
Analysts often misapply P/S multiples used for software companies to ZCMD, which obscures the reality that its revenue is transactional and highly sensitive to pharmaceutical marketing budgets. A more appropriate metric would be a focus on cash-burn-adjusted book value, as the company's current operational structure lacks the recurring revenue characteristics required to justify traditional tech-sector valuation premiums.